APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Intravitreal Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti-VEGF Intravitreal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025180 pages

Choose your research edition.

Industry ResearchAnti-VEGF Intravitreal Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Intravitreal Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Intravitreal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Intravitreal Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Intravitreal Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Anti-VEGF Intravitreal Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti-VEGF Intravitreal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-VEGF Intravitreal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-VEGF Intravitreal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti-VEGF Intravitreal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-VEGF Intravitreal Drugs include Qilu Pharma, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences, Biogen and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-VEGF Intravitreal Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-VEGF Intravitreal Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-VEGF Intravitreal Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-VEGF Intravitreal Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-VEGF Intravitreal Drugs Segment by Company

Qilu Pharma

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Roche

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biogen

Biocon Biologics

Anti-VEGF Intravitreal Drugs Segment by Type

Aflibercept

Brolucizumab

Faricimab

Conbercept

Ranibizumab

Other

Anti-VEGF Intravitreal Drugs Segment by Application

Age-related Macular Degeneration

Retinal Vein Occlusion

Diabetic Macular Edema

Other

Anti-VEGF Intravitreal Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Intravitreal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Intravitreal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Intravitreal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-VEGF Intravitreal Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-VEGF Intravitreal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti-VEGF Intravitreal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti-VEGF Intravitreal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti-VEGF Intravitreal Drugs Industry Trends Table 2. Anti-VEGF Intravitreal Drugs Industry Drivers Table 3. Anti-VEGF Intravitreal Drugs Industry Opportunities and Challenges Table 4. Anti-VEGF Intravitreal Drugs Industry Restraints Table 5. Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti-VEGF Intravitreal Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers Table 9. Global Anti-VEGF Intravitreal Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Anti-VEGF Intravitreal Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti-VEGF Intravitreal Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti-VEGF Intravitreal Drugs Manufacturers, Product Type & Application Table 13. Global Anti-VEGF Intravitreal Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-VEGF Intravitreal Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aflibercept Table 17. Major Manufacturers of Brolucizumab Table 18. Major Manufacturers of Faricimab Table 19. Major Manufacturers of Conbercept Table 20. Major Manufacturers of Ranibizumab Table 21. Major Manufacturers of Other Table 22. Global Anti-VEGF Intravitreal Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 24. Global Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 25. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2026) Table 26. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2027-2032) Table 27. Global Anti-VEGF Intravitreal Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (K Units) Table 29. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (K Units) Table 30. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Age-related Macular Degeneration Table 33. Major Manufacturers of Retinal Vein Occlusion Table 34. Major Manufacturers of Diabetic Macular Edema Table 35. Major Manufacturers of Other Table 36. Global Anti-VEGF Intravitreal Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 38. Global Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 39. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2026) Table 40. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2027-2032) Table 41. Global Anti-VEGF Intravitreal Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (K Units) Table 43. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (K Units) Table 44. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2026) Table 45. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2027-2032) Table 46. Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Anti-VEGF Intravitreal Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021-2026) Table 49. Global Anti-VEGF Intravitreal Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Anti-VEGF Intravitreal Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 53. North America Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 54. Europe Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 56. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Anti-VEGF Intravitreal Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Anti-VEGF Intravitreal Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Anti-VEGF Intravitreal Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021-2026) Table 67. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2027-2032) Table 68. Qilu Pharma Company Information Table 69. Qilu Pharma Business Overview Table 70. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio Table 72. Qilu Pharma Recent Development Table 73. Chengdu Kanghong Pharmaceutical Company Information Table 74. Chengdu Kanghong Pharmaceutical Business Overview Table 75. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio Table 77. Chengdu Kanghong Pharmaceutical Recent Development Table 78. Samsung Bioepis Company Information Table 79. Samsung Bioepis Business Overview Table 80. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio Table 82. Samsung Bioepis Recent Development Table 83. Roche Company Information Table 84. Roche Business Overview Table 85. Roche Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Roche Anti-VEGF Intravitreal Drugs Product Portfolio Table 87. Roche Recent Development Table 88. Regeneron Pharmaceuticals Company Information Table 89. Regeneron Pharmaceuticals Business Overview Table 90. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio Table 92. Regeneron Pharmaceuticals Recent Development Table 93. Novartis Company Information Table 94. Novartis Business Overview Table 95. Novartis Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Novartis Anti-VEGF Intravitreal Drugs Product Portfolio Table 97. Novartis Recent Development Table 98. Coherus BioSciences Company Information Table 99. Coherus BioSciences Business Overview Table 100. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio Table 102. Coherus BioSciences Recent Development Table 103. Biogen Company Information Table 104. Biogen Business Overview Table 105. Biogen Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Biogen Anti-VEGF Intravitreal Drugs Product Portfolio Table 107. Biogen Recent Development Table 108. Biocon Biologics Company Information Table 109. Biocon Biologics Business Overview Table 110. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio Table 112. Biocon Biologics Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Anti-VEGF Intravitreal Drugs Distributors List Table 116. Anti-VEGF Intravitreal Drugs Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Anti-VEGF Intravitreal Drugs Product Image Figure 2. Global Anti-VEGF Intravitreal Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Intravitreal Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-VEGF Intravitreal Drugs Sales (2021-2032) & (K Units) Figure 5. Global Anti-VEGF Intravitreal Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anti-VEGF Intravitreal Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aflibercept Image Figure 9. Brolucizumab Image Figure 10. Faricimab Image Figure 11. Conbercept Image Figure 12. Ranibizumab Image Figure 13. Other Image Figure 14. Global Anti-VEGF Intravitreal Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Anti-VEGF Intravitreal Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Anti-VEGF Intravitreal Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2032) Figure 20. Age-related Macular Degeneration Image Figure 21. Retinal Vein Occlusion Image Figure 22. Diabetic Macular Edema Image Figure 23. Other Image Figure 24. Global Anti-VEGF Intravitreal Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Anti-VEGF Intravitreal Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2032) Figure 27. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Anti-VEGF Intravitreal Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021-2032) Figure 44. China Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Anti-VEGF Intravitreal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Anti-VEGF Intravitreal Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Anti-VEGF Intravitreal Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Anti-VEGF Intravitreal Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Aflibercept
  • Brolucizumab
  • Faricimab
  • Conbercept
  • Ranibizumab
  • Other
Applications
  • Age-related Macular Degeneration
  • Retinal Vein Occlusion
  • Diabetic Macular Edema
  • Other
Companies covered
  • Qilu Pharma
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Roche
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biogen
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-VEGF Intravitreal Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-VEGF Intravitreal Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti-VEGF Intravitreal Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti-VEGF Intravitreal Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti-VEGF Intravitreal Drugs Market Dynamics
  1. 2.1 Anti-VEGF Intravitreal Drugs Industry Trends
  2. 2.2 Anti-VEGF Intravitreal Drugs Industry Drivers
  3. 2.3 Anti-VEGF Intravitreal Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Intravitreal Drugs Industry Restraints
3 Anti-VEGF Intravitreal Drugs Market by Manufacturers
  1. 3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti-VEGF Intravitreal Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti-VEGF Intravitreal Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti-VEGF Intravitreal Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-VEGF Intravitreal Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti-VEGF Intravitreal Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Anti-VEGF Intravitreal Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-VEGF Intravitreal Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-VEGF Intravitreal Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-VEGF Intravitreal Drugs Tier 1, Tier 2, and Tier 3
4 Anti-VEGF Intravitreal Drugs Market by Type
  1. 4.1 Anti-VEGF Intravitreal Drugs Type Introduction
  2. 4.1.1 Aflibercept
  3. 4.1.2 Brolucizumab
  4. 4.1.3 Faricimab
  5. 4.1.4 Conbercept
  6. 4.1.5 Ranibizumab
  7. 4.1.6 Other
  8. 4.2 Global Anti-VEGF Intravitreal Drugs Sales by Type
  9. 4.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Anti-VEGF Intravitreal Drugs Revenue by Type
  13. 4.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2032)
5 Anti-VEGF Intravitreal Drugs Market by Application
  1. 5.1 Anti-VEGF Intravitreal Drugs Application Introduction
  2. 5.1.1 Age-related Macular Degeneration
  3. 5.1.2 Retinal Vein Occlusion
  4. 5.1.3 Diabetic Macular Edema
  5. 5.1.4 Other
  6. 5.2 Global Anti-VEGF Intravitreal Drugs Sales by Application
  7. 5.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Anti-VEGF Intravitreal Drugs Revenue by Application
  11. 5.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032)
6 Global Anti-VEGF Intravitreal Drugs Sales by Region
  1. 6.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-VEGF Intravitreal Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Anti-VEGF Intravitreal Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti-VEGF Intravitreal Drugs Revenue by Region
  1. 7.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region
  2. 7.1.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti-VEGF Intravitreal Drugs Revenue (2021-2032)
  8. 7.2.2 North America Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti-VEGF Intravitreal Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti-VEGF Intravitreal Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Qilu Pharma
  2. 8.1.1 Qilu Pharma Company Information
  3. 8.1.2 Qilu Pharma Business Overview
  4. 8.1.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
  6. 8.1.5 Qilu Pharma Recent Developments
  7. 8.2 Chengdu Kanghong Pharmaceutical
  8. 8.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 8.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 8.2.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
  12. 8.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 8.3 Samsung Bioepis
  14. 8.3.1 Samsung Bioepis Company Information
  15. 8.3.2 Samsung Bioepis Business Overview
  16. 8.3.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
  18. 8.3.5 Samsung Bioepis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Regeneron Pharmaceuticals
  26. 8.5.1 Regeneron Pharmaceuticals Company Information
  27. 8.5.2 Regeneron Pharmaceuticals Business Overview
  28. 8.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
  30. 8.5.5 Regeneron Pharmaceuticals Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Coherus BioSciences
  38. 8.7.1 Coherus BioSciences Company Information
  39. 8.7.2 Coherus BioSciences Business Overview
  40. 8.7.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
  42. 8.7.5 Coherus BioSciences Recent Developments
  43. 8.8 Biogen
  44. 8.8.1 Biogen Company Information
  45. 8.8.2 Biogen Business Overview
  46. 8.8.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
  48. 8.8.5 Biogen Recent Developments
  49. 8.9 Biocon Biologics
  50. 8.9.1 Biocon Biologics Company Information
  51. 8.9.2 Biocon Biologics Business Overview
  52. 8.9.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
  54. 8.9.5 Biocon Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-VEGF Intravitreal Drugs Value Chain Analysis
  2. 9.1.1 Anti-VEGF Intravitreal Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-VEGF Intravitreal Drugs Production Mode & Process
  6. 9.2 Anti-VEGF Intravitreal Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-VEGF Intravitreal Drugs Distributors
  9. 9.2.3 Anti-VEGF Intravitreal Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst